Kristin Abate sold $5,260 of KPTI
Chief Accounting Officer at Karyopharm Therapeutics Inc.. 559 shares at an average of $9.41, traded Mar 2, 2026, filed Mar 3, 2026.
Score components
- +15RoleOfficer
- 0Trade size$5k at market
- 0Share of holdings soldSold 2.5% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -35.5%, 3m +1.1%, 6m -79.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002045943-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | SOpen-market sale Common Stock | -559 | $9.41 | $5,260 | 22,063 | Mar 3, 2026 |
Related signals
Other insiders at Karyopharm Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $450 378 shares | -2% | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $38 19 shares | -0% | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Stuart Poulton EVP, Chief Development Officer | $1,342 189 shares | -0% | |
| 30Weak | Karyopharm Therapeutics Inc. | Kristin Abate Chief Accounting Officer | $504 53 shares | -0% | |
| 30Weak | Karyopharm Therapeutics Inc. | Sohanya Roshan Cheng EVP & Chief Commercial Officer | $3,078 324 shares | -0% | |
| 30Weak | Karyopharm Therapeutics Inc. | Michael Mano EVP, CLO&Secretary | $2,527 266 shares | -0% | |
| 40Moderate | Karyopharm Therapeutics Inc. | Richard A. Paulson President and CEO | $21k 2,203 shares | -1% | |
| 30Weak | Karyopharm Therapeutics Inc. | Reshma Rangwala EVP & Chief Medical Officer | $3,876 408 shares | -1% | |
| 30Weak | Karyopharm Therapeutics Inc. | Stuart Poulton EVP, Chief Development Officer | $3,829 403 shares | -0% | |
| 15Weak | KPTIsell Karyopharm Therapeutics Inc. | Reshma Rangwala EVP & Chief Medical Officer | $4,014 449 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.